探索Danggui Buxue抗性结肠炎的主要目标和机制:网络药理学和实验验证
Wen-Juan Liu1, Shan-Bo Ma2, Jia-Xin Li1
1Key Laboratory of Shaanxi Administration of Traditional Chinese Medicine for TCM Compatibility, Shaanxi University of Chinese Medicine, Xianyang, 712046, China.
Journal of ethnopharmacology
|March 5, 2025
概括
丹古伊布克苏 (Danggui Buxue) (DBD) 通过减少肠道炎症和保护肠道内膜,有效治疗性结肠炎 (UC). 它的治疗效益与抑制PI3K/AKT信号通路有关.
科学领域:
- 综合医学是一个整体的医学.
- 药理学 药理学是指药理学的学科.
- 胃肠病学 胃肠病学
背景情况:
- 丹圭布克苏 (Danggui Buxue decoction,简称DBD) 是一种传统的中国草药配方,以清气调和血液生产而闻名.
- DBD用于月经性贫血和慢性,但其对性结肠炎 (UC) 的影响尚未探索.
研究的目的:
- 研究DBD对UC的治疗作用和机制.
- 结合网络药理学和实验验证,进行全面的分析.
主要方法:
- 网络药理学预测了DBD的目标和UC的途径.
- 实验验证使用硫酸 (DSS) 诱导的UC小鼠模型.
- 西部斑点分析评估PI3K/AKT通路中的蛋白质表达.
主要成果:
- 确定了27个活性成分,265个DBD目标和5867个UC基因,共有172个共同目标.
- 网络分析显示了2359个GO术语和157个KEGG路径.
- 在UC小鼠模型中,DBD治疗减少了肠道炎症和结肠损伤,抑制了PI3K/AKT通路.
结论:
- DBD显著减轻结肠炎症,并保持UC的肠粘膜完整性.
- DBD的抗UC疗效是由PI3K/AKT通路的抑制介导的.
相关概念视频
Pathophysiology of Peptic Ulcer Disease: Mucosal Defense Factors
1.6K
Peptic ulcer disease, commonly called PUD, represents a multifaceted condition characterized by disruptions in the lining of the gastrointestinal (GI) tract. Central to the protection of the gastrointestinal lining is the mucosal-bicarbonate barrier. This physiological defense mechanism is a formidable shield against the corrosive effects of gastric acid and pepsin secretion in the stomach. Its role is pivotal in maintaining the structural integrity of the stomach's inner lining.
1.6K
Drugs for Peptic Ulcer Disease: Prostaglandin Analogs as Mucosal Protective Agents
1.6K
The gastric mucosa produces prostaglandins E2 (PGE2) and prostacyclin (PGI2), crucial in maintaining gastric health. They exert cytoprotective effects, including increasing bicarbonate secretion, releasing protective mucin, reducing gastric acid output, and preventing harmful vasoconstriction. These effects are mediated through various receptors, such as EP1, EP2, EP3, and EP4.
Non-steroidal anti-inflammatory drugs (NSAIDs) can induce peptic ulcers by inhibiting cyclooxygenase, decreasing...
Non-steroidal anti-inflammatory drugs (NSAIDs) can induce peptic ulcers by inhibiting cyclooxygenase, decreasing...
1.6K
Drugs for Treatment of Diarrhea-Predominant IBS
924
Diarrhea-predominant irritable bowel syndrome (IBS-D) is a subtype of IBS characterized primarily by frequent, loose, or watery stools, abdominal pain, and abdominal discomfort. Therapeutic approaches to managing IBS-D include dietary changes, stress management techniques, and pharmaceutical interventions.
Two specific drugs used in the treatment are alosetron (Lotronex) and eluxadoline (Viberzi). Alosetron, a 5-HT3 antagonist, works by slowing the movement of stools in the gut, reducing bowel...
Two specific drugs used in the treatment are alosetron (Lotronex) and eluxadoline (Viberzi). Alosetron, a 5-HT3 antagonist, works by slowing the movement of stools in the gut, reducing bowel...
924
Drugs for Treatment of Ulcerative Colitis in IBD
667
Ulcerative colitis is a chronic inflammatory condition primarily affecting the colon and rectum. The primary drugs used in the treatment of ulcerative colitis are aminosalicylates. They exhibit anti-inflammatory and immunosuppressive properties. They modulate inflammatory mediators and inhibit the activity of nuclear factor κB (NF-κB). Aminosalicylates also reduce inflammation by inhibiting prostaglandin and leukotriene production and decreasing neutrophil chemotaxis and superoxide...
667
Peptic Ulcer Disease IV: Management
676
Medical treatment strategies for peptic ulcers encompass various methods. The primary goal of treatment is to diminish gastric acidity and strengthen mucosal defense mechanisms.
The therapeutic approach involves ensuring adequate rest, implementing drug therapy, promoting smoking cessation, making dietary modifications, and emphasizing long-term follow-up care.
Pharmacological management
The prevailing therapy for peptic ulcers involves a combination of managing the patient's current...
The therapeutic approach involves ensuring adequate rest, implementing drug therapy, promoting smoking cessation, making dietary modifications, and emphasizing long-term follow-up care.
Pharmacological management
The prevailing therapy for peptic ulcers involves a combination of managing the patient's current...
676
Inflammatory Bowel Disease I: Ulcerative Colitis
1.5K
Introduction
Inflammatory bowel disease, or IBD, encompasses a group of disorders characterized by chronic inflammation or ulceration of the gastrointestinal tract.
Risk Factors
The exact cause of IBD remains unclear, although it is believed to be due to a mix of genetic, environmental, microbial, and immune factors. Genetic factors are significant in determining susceptibility to IBD, with family history being a critical risk factor. Individuals with a first-degree relative who has IBD are at...
Inflammatory bowel disease, or IBD, encompasses a group of disorders characterized by chronic inflammation or ulceration of the gastrointestinal tract.
Risk Factors
The exact cause of IBD remains unclear, although it is believed to be due to a mix of genetic, environmental, microbial, and immune factors. Genetic factors are significant in determining susceptibility to IBD, with family history being a critical risk factor. Individuals with a first-degree relative who has IBD are at...
1.5K


